We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$625M
AUM Growth
+$350M
Cap. Flow
+$12.1M
Cap. Flow %
1.94%
Top 10 Hldgs %
74.87%
Holding
79
New
22
Increased
18
Reduced
8
Closed
20

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$13.9M
2
AZN icon
AstraZeneca
AZN
+$9.59M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$7.78M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$5.91M
5
ESTA icon
Establishment Labs
ESTA
+$5.67M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$9.29M
2
BBIO icon
BridgeBio Pharma
BBIO
+$8.24M
3
CYTK icon
Cytokinetics
CYTK
+$6.63M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.53M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$4.09M

Sector Composition

Rank Sector Weight
1 Miscellaneous 64.24%
2 Healthcare 34.01%
3 Financials 1.56%
4 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
$339M 54.19%
+750,000
New +$334M
NARI
2
DELISTED
Inari Medical, Inc. Common Stock
NARI
$19.9M 3.19%
220,000
+95,000
+76% +$7.78M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$18.7M 2.99%
465,654
+66,352
+17% +$2.78M
KURA icon
4
Kura Oncology
KURA
$1.17B
$14.9M 2.38%
924,147
+364,147
+65% +$5.26M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.8B
$14.1M 2.25%
+120,000
New +$13.9M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$13.9M 2.23%
247,000
-51,545
-17% -$2.95M
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.8M 2.21%
845,155
+290,000
+52% +$3.94M
ESTA icon
8
Establishment Labs
ESTA
$2.15B
$11.8M 1.88%
174,500
+97,000
+125% +$5.67M
AZN icon
9
AstraZeneca
AZN
$256B
$10.6M 1.7%
+80,000
New +$9.59M
ZNTL icon
10
Zentalis Pharmaceuticals
ZNTL
$389M
$9.57M 1.53%
207,500
+90,000
+77% +$4.85M
SWTX
11
PUT
DELISTED
SpringWorks Therapeutics
SWTX
$9.03M 1.44%
+160,000
New +$9.16M
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.5B
$7.36M 1.18%
75,000
+10,000
+15% +$843K
PTGX icon
13
Protagonist Therapeutics
PTGX
$9.63B
$7.1M 1.14%
300,000
+58,881
+24% +$1.66M
ARYE
14
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$6.83M 1.09%
702,500
– –
RPTX
15
DELISTED
Repare Therapeutics
RPTX
$6.68M 1.07%
468,905
+197,127
+73% +$2.92M
PMVP icon
16
CALL
PMV Pharmaceuticals
PMVP
$66.3M
$6.61M 1.06%
+317,400
New +$5.6M
LNTH icon
17
Lantheus
LNTH
$6.59B
$6.36M 1.02%
+115,000
New +$4.32M
NSTG
18
DELISTED
NanoString Technologies, Inc.
NSTG
$5.96M 0.95%
+171,592
New +$5.91M
VINC
19
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$5.5M 0.88%
68,705
+11,937
+21% +$1.47M
PTGX icon
20
PUT
Protagonist Therapeutics
PTGX
$9.63B
$5.11M 0.82%
+215,900
New +$6.08M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$416M
$4.76M 0.76%
300,000
+135,000
+82% +$2.33M
CLDX icon
22
Celldex Therapeutics
CLDX
$3.09B
$4.26M 0.68%
125,000
+25,000
+25% +$799K
BLU
23
DELISTED
BELLUS Health Inc.
BLU
$4.13M 0.66%
600,000
+100,000
+20% +$644K
CBAY
24
DELISTED
Cymabay Therapeutics
CBAY
$3.96M 0.63%
1,272,244
+150,000
+13% +$472K
CRSP icon
25
CALL
CRISPR Therapeutics
CRSP
$5.46B
$3.45M 0.55%
+55,000
New +$3.45M
1
2 3

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Affinity Asset Advisors held 79 positions worth $625M, up 127% from $275M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Affinity Asset Advisors's Q1 2022 filing shows 22 new, 18 increased, 8 reduced and 20 closed positions. Its largest new stake was Ascendis Pharma A/S: 120,000 shares worth $14.1M. The largest sale was Arena Pharmaceuticals Inc, an estimated $9.29M.

By sector, the portfolio is most concentrated in Miscellaneous at 64% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • Affinity Asset Advisors's largest Q1 2022 buy was Ascendis Pharma A/S: 120,000 shares worth $14.1M.
  • Affinity Asset Advisors added most to Inari Medical, Inc. Common Stock in Q1 2022, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q1 2022 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $4.53M.
  • Affinity Asset Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $9.29M.
  • Affinity Asset Advisors's ten largest holdings make up 75% of its $625M portfolio in Q1 2022.
  • Affinity Asset Advisors opened 22 new positions and closed 20 in Q1 2022.
  • Affinity Asset Advisors's portfolio value rose 127% quarter-over-quarter to $625M.

Based on Affinity Asset Advisors's 13F filing for Q1 2022, filed 13 May 2022.